Search

everythinglearnresearchcommunity

for

Search:↓

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

People with alopecia areata have fewer regulatory T-cells than those with other skin conditions.

Researchers found that certain miRNAs, which affect immune system regulation, are differently expressed in mice with a hair loss condition compared to healthy mice.

ODC expression in mouse skin and tumors is varied and can be inhibited by retinoic acid or cycloheximide.

The humanized AA mouse model is better for testing new alopecia areata treatments.

Increasing regulatory T cells may help treat alopecia areata by reducing autoimmunity and promoting hair growth.

Type XVII collagen helps control skin cell growth and could be a target for anti-aging treatments.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

7DHC and BM15766 damage hair follicle structure and reduce key gene expression.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

TS-13 effectively stops tumor growth and reduces chemotherapy side effects.

Autoimmune reactions may cause both alopecia areata and HAM.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Hedgehog pathway inhibitors could be effective in treating melanoma.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Scientists made a mouse model of a serious skin cancer by changing skin cells with a virus and a specific gene, which is similar to the disease in humans.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

LHTric-1 is a specific antibody useful for studying hair and nail formation.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Analog 23 is a promising compound for prostate cancer treatment.

SH-340 may improve skin barrier and help treat atopic dermatitis.

MR antagonists may improve skin health and wound healing, especially in aging.

Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.

Certain immune cells are linked to non-scarring hair loss, suggesting potential for immune-targeted treatments.

Adalimumab helped control a child's severe eye disease when other treatments failed.

HPV genes and estradiol increase a cancer-related signaling pathway, which may be targeted for cervical cancer treatment.